Results 1 to 10 of about 6,111 (249)
Tofacitinib for Pityriasis Rubra Pilaris: A Case Report [PDF]
Clinical, Cosmetic and Investigational DermatologyHongyan Tan, Bin Zhang, Xiawei Kang, Lvyao Wang, Xiao Qiu, Xiangyu Hu Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People’s Republic of ChinaCorrespondence: Xiangyu Hu, Email 369930758@qq.comPurpose ...
Tan H +5 more
doaj +7 more sources
Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review [PDF]
Frontiers in MedicineBackgroundPityriasis rubra pilaris is a chronic, scaly, keratotic skin disease, mainly manifested as scaly plaques and keratinized hair follicles. This condition significantly impacts the patient’s quality of life and is considered one of the intractable
Xiaofang Zhang +7 more
doaj +6 more sources
Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report [PDF]
SAGE Open Medical Case Reports, 2023 Pityriasis rubra pilaris is a rare inflammatory dermatosis characterized by orange-red confluent plaques, hyperkeratotic follicular papules, palmoplantar keratoderma, and, in some cases, erythroderma.
Mysa Saad, Alison Spurr, Jennifer Lipson
doaj +3 more sources
Juvenile Pityriasis Rubra Pilaris [PDF]
Dermatology Practical & Conceptual, 2023 Yihang Xie +3 more
doaj +4 more sources
Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
Skin Health and Disease, 2023 Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67‐year‐old man with Pityriasis rubra pilaris might induced by COVID‐19 vaccination.
Ya‐ting Liu, Shang‐shang Wang
doaj +2 more sources
Pityriasis rubra pilaris presenting with an abnormal autoimmune profile: two case reports [PDF]
Journal of Medical Case Reports, 2009 Introduction Pityriasis rubra pilaris is an uncommon inflammatory and hyperproliferative dermatosis of juvenile or adult onset. The etiology of the disease is still unknown.
Gregoriou Stamatis +5 more
doaj +4 more sources
SAGE Open Medical Case Reports, 2022 Classic adult pityriasis rubra pilaris is a severe papulosquamous disease that tends to resolve in 3–5 years but can have a devastating impact on patients while active.
Celina DeBiasio +3 more
doaj +2 more sources
Oral Alitretinoin for the Treatment of Recalcitrant Pityriasis Rubra Pilaris [PDF]
Case Reports in Dermatology, 2011 Treatment of pityriasis rubra pilaris is still challenging. We here present a 74-year-old woman who had not experienced stable remission of her skin symptoms during prior treatments including topical and systemic corticosteroids, phototherapy, orally ...
Laurenz Schmitt +2 more
doaj +4 more sources
Drug-related pityriasis rubra pilaris with acantholysis [PDF]
Vojnosanitetski Pregled, 2013 Introduction. Acantholysis is rarely reported histological feature of Pityriasis rubra pilaris (PRP), recently recognized as having diagnostic specificity for differentiating PRP from psoriasis. Case report.
Gajinov Zorica T. +5 more
doaj +3 more sources
Refractory pityriasis rubra pilaris treated with abrocitinib [PDF]
Dermatology ReportsPityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts the quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor
Filip Rob
doaj +2 more sources